Searchable abstracts of presentations at key conferences in endocrinology

ea0070oc6.5 | Hot Topics (including COVID-19 | ECE2020

TransCon PTH, a long-acting PTH, in patients with hypoparathyroidism: Results of the phase 2 PaTH forward trial

Sikjaer Tanja , Rejnmark Lars , Khan Aliya , Schwarz Peter , Vokes Tamara , Clarke Bart , Rubin Mishaela , Hofbauer Lorenz , Eriksen Erik , Palermo Andrea , Pagotto Uberto , Marcocci Claudio , Ahmed Intekhab , Mourya Sanchita , Markova Denka , Karpf David B

Background: Hypoparathyroidism (HP) is characterized by low serum calcium (sCa) and high serum phosphate (sP). Standard of care (SoC), active vitamin D and calcium, raises sCa and sP and increases burden of illness on HP patients by worsening hypercalciuria and the CaxP product. Parathyroid hormone (PTH)(1–84)(t1/2 ~2–3 hrs) is approved and can raise sCa and allow partial withdrawal of SoC, but does not sufficiently control urine calcium or symptoma...